Filing Overview
Registrant: Jupiter Wellness, Inc. The supplied metadata identifies BONK, Inc., but the filing names Jupiter Wellness, Inc. as the registrant. This Form 8-K reports events dated August 22, 2022 and August 18, 2022, and was filed on August 26, 2022.
Material Agreements and Financial Impact
Amendment to Asset Purchase Agreement
Jupiter Wellness amended its asset purchase agreement with Applied Biology Inc. The original consideration of 2,000,000 restricted common shares was replaced with aggregate cash consideration of $200,000:
- $100,000 payable on the August 22, 2022 effective date.
- $100,000 payable within 60 days of the effective date.
Termination of Forbearance and Settlement Agreement
The company reported that substantially all personal property assets of Benuvia, Inc. and related debtors were sold publicly on August 18, 2022. The assets had been pledged as collateral to Benuvia Holdings, LLC.
- Aggregate purchase price for the collateral: $8.1 million.
- Amount owed to Benuvia Holdings as of August 4, 2022: more than $33.105 million.
- Jupiter Wellness stated that it received no proceeds from the asset sale.
The filing indicates that the previously disclosed Forbearance and Settlement Agreement was terminated or otherwise rendered ineffective in connection with these developments. The filing text does not provide a clear value for any additional impairment, reserve, or loss recognized by Jupiter Wellness.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, net income, operating cash flow, margins, total debt, cash balances, liquidity measures, or comparative-period financial results. It does disclose a $200,000 cash purchase obligation and the loss of expected proceeds associated with the Benuvia collateral.
Outlook, Risks, and Unusual Items
- The amended Applied Biology transaction creates a cash funding obligation of $200,000, with the second installment due within 60 days of August 22, 2022.
- The Benuvia collateral sale yielded no proceeds for Jupiter Wellness, creating a material collection risk under the prior settlement arrangement.
- The filing provides no management guidance, revenue outlook, or forecast.
- The principal unusual item is the substitution of cash consideration for 2,000,000 restricted shares in the Applied Biology acquisition agreement.
Investor Verification Items
- Confirm the registrant identity, because the supplied metadata says BONK, Inc. while the filing identifies Jupiter Wellness, Inc. and ticker JUPW.
- Verify whether both $100,000 payments under the amended asset purchase agreement were made and assess the acquired assets and transaction rationale.
- Review subsequent filings for the accounting treatment of the Benuvia arrangement and any write-off or impairment resulting from receiving no proceeds.
- Check subsequent liquidity disclosures for the company’s ability to fund the $200,000 purchase obligation.
- Review later filings for developments involving Benuvia, the collateral sale, or related creditor claims.